- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05108480
Self-myofascial Release With Foam Roller in Patients With Hemophilic Knee Arthropathy
Prospective and Multicenter Study to Assess the Safety and Effectiveness of a Physiotherapy Treatment Through Self-myofascial Release With Foam Roller in Patients With Hemophilic Knee Arthropathy: A Randomized Clinical Trial
Introduction: Hemophilic ankle arthropathy is manifested by degenerative functional alterations (deficit of muscular strength, mobility and proprioception) (intra-articular alterations) and chronic pain. Myofascial release techniques are used to treat soft tissue adhesions, relieve pain, and reduce tissue sensitivity.
Design. A randomized clinical trial. Directed: To evaluate the safety and effectiveness of a myofascial self-release protocol with Foam Roller applied in patients with hemophilic knee arthropathy.
Patients: 58 patients with knee arthropathy will be recruited for inclusion in the study. The patients will be recruited in 5 centers, from different regions of Spain.
Intervention: Each session will last approximately 15 minutes, with five physical therapy sessions per week over a period of 8 weeks. Patients will be evaluated at the beginning of the study, after the intervention and after a follow-up period of 2 months. The treatment program includes 11 exercises to be administered bilaterally. A mobile application will be developed where each patient can observe the exercises to be performed.
Measurement instruments and study variables: digital goniometer (ankle range of motion); visual analog scale and pressure algometer (joint pain); Hemophilia Joint Health Score (Joint Condition); dynamometer evaluation (muscle strength); 6-minute walk test (lower extremity functionality); Mobile device (activity log); Finger floor test (muscle flexibility). At the same time, the study will make it possible to determine the joint bleeding caused by the applied physiotherapy treatment.
Expected results: demonstrate the safety of this physiotherapy technique in patients with hemophilia. Likewise, an improvement in ankle pain, function and joint movement is expected.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Murcia, Spain, 30006
- University of Murcia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a medical diagnosis of hemophilia A or B.
- Patients with a severe phenotype of hemophilia (<1% FVIII/FIX).
- Patients with a medical diagnosis of hemophilic knee arthropathy and more than 3 points on the Hemophilia Joint Health Score.
- Being over 18 years old.
- No scheduled orthopedic surgeries during the study phase
Exclusion Criteria:
- Patients with hemarthrosis in the month before the beginning of the study.
- Patients unable to walk.
- Severe functional alterations of the upper limb that prevented the exercises.
- Failure to sign the informed consent document
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Self-myofascial release
Each session will last approximately 15 minutes, with five physiotherapy sessions taking place over a period of 2 months.
The Self-Myofascial release protocol for the lower limbs using a Foam Roller and and Solid Ball Massage, adapted to patients with hemophilic ankle arthropathy will include: Self-Myofascial release of the plantar region using and Solid Ball Massage; Release of the myofascial components of the back of the leg using a Foam Roller; Release of the myofascial components of the anterior part of the leg using a Foam Roller; Release of myofascial components of the hamstring region using a Foam Roller; Release of the myofascial components of the adductor muscles using a Solid Ball Massage in a sitting position; Release of the myofascial components of the abductor muscles using a Foam Roller in lateral decubitus; Release of the myofascial components of the pelvitrochanterian muscles using a Foam Roller in a sitting position.
|
This study followed the protocol designed for patients with hemophilic knee arthropathy.
For its implementation, a 30-cm long15-cm diameter foam roller was used, and a ball 22 cm in length and 8 cm in diameter.
The total duration of the intervention was 15 minutes, with 7 sessions per week over a period of 8 weeks.
The physiotherapist who supervised the intervention followed up on all patients by telephone on a weekly basis to check for the absence of haemarthrosis during the intervention and to detect the possible need for protocol adaptations depending on the clinical situation of each patient.
Each patient was individually provided with instructions as to how perform the exercises during the pretreatment evaluation, customizing the program if necessary.
All patients had access to a mobile application, designed ad hoc for the research study (He-Foam®), where they could learn about the exercises through demonstration videos.
|
No Intervention: Control group
The subjects included in the control group will not receive Physiotherapy sessions and will continue with their usual routine of activity and physical exercise, and with the same drug treatment schedule with FVIII / FIX and analgesic drugs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline knee joint pain after treatment and at 2 months
Time Frame: Screening visit, within the first seven days after treatment and after two months follow-up visit
|
Visual analogic scale (VAS).
This scale will be used to evaluate the perception of joint pain, where knee joint pain ranges from 0 to 10 points (no pain to maximum perceived pain).
|
Screening visit, within the first seven days after treatment and after two months follow-up visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline knee pressure pain threshold after treatment and at 2 months
Time Frame: Screening visit, within the first seven days after treatment and after two months follow-up visit
|
Pressure algometer.
Measuring instrument used to evaluate pressure joint pain.
The instrument shall consist of a measuring device attached to a hard rubber tip 1.1 cm in diameter.
Its sphere shall be calibrated in kg/cm2 with divisions of 0.1 kg/cm2.
The pressure algometry methodology applied was based mainly on the study by Hogeweg.
Before taking the measurements, patients will be instructed to say "yes" as soon as pressure exerted by the algometer becomes slightly unpleasant.
The pressure algometer shall be kept perpendicular to the surface of the skin with the right hand, stabilizing the axis of the instrument using the thumb and index finger of the left hand.
The pressure shall be increased at a uniform rate of approximately 1 kg/cm2 per second.
As soon as the subject, according to the instructions, says "yes", the pressure will be stopped and the score will be noted.
|
Screening visit, within the first seven days after treatment and after two months follow-up visit
|
Change from baseline knee joint status after treatment and at 2 months
Time Frame: Screening visit, within the first seven days after treatment and after two months follow-up visit
|
Hemophilia Joint Health Score (HJHS).
This measuring instrument will be used to evaluate the joint condition of knees.
It includes 8 items (inflammation and its duration, pain, atrophy and muscle strength, crepitus, and reduced flexion and extension) ranging from 0 to 20 points per joint (the higher the score, the greater the joint deterioration).
|
Screening visit, within the first seven days after treatment and after two months follow-up visit
|
Change from baseline knee range of motion after treatment and at 2 months
Time Frame: Screening visit, within the first seven days after treatment and after two months follow-up visit
|
Goniometry.
Knee range of motion shall be measured using a goniometer.
The assessment can be made with the patient standing.
This measuring instrument allows more accurate measurements than those obtained with a universal goniometer
|
Screening visit, within the first seven days after treatment and after two months follow-up visit
|
Change from baseline knee muscles strength after treatment and at 2 months
Time Frame: Screening visit, within the first seven days after treatment and after two months follow-up visit
|
Dynamometry.
The maximum isometric strength of the flexor and extensor muscles of the knee joint will be evaluated on both limbs with a manual dynamometer using a mark test.
For this test, the rater needs to keep the dynamometer stationary while the patient exerts maximum force against it.
|
Screening visit, within the first seven days after treatment and after two months follow-up visit
|
Change from baseline muscle flexibility after treatment and at 2 months
Time Frame: Screening visit, within the first seven days after treatment and after two months follow-up visit
|
Fingertip-to-Floor Test.
This test is used to assess the degree of flexibility of the posterior muscles of the lower limbs.
This value is calculated as the distance between the fingertip and the floor when maximum hip flexion with knee extension is performed
|
Screening visit, within the first seven days after treatment and after two months follow-up visit
|
Change from baseline of muscle activation of the quadriceps after treatment and at 2 months
Time Frame: Screening visit, within the first seven days after treatment and after two months follow-up visit
|
Muscle activation of the quadriceps was evaluated with surface electromyography (surface electromyography model; Shimmer Sensing, Dublin, Ireland).
Electrodes were placed accord-ing to the European recommendations for the use of surface electromyography.
Bipo-lar rectangular silver/silver chloride (Ag/AgCl) electrodes were used, measuring 28 x 44 mm (Ambu® WhiteSensor 4200 model) with a 46 mm2 measurement area, 2 cm apart.
For the patients to reach their maximum muscle strength, the rater provided the same verbal stimulus to motivate all the patients with each contraction.
|
Screening visit, within the first seven days after treatment and after two months follow-up visit
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- He-FoamKnee
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Haemophilia
-
Al-Azhar UniversityActive, not recruiting
-
University of ValenciaUnknown
-
Novo Nordisk A/SCompletedHaemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia BFrance, United States, India, Mexico, United Kingdom, Netherlands, Sweden, Korea, Republic of, Spain, Switzerland, Serbia, Turkey, Bulgaria, Italy, Japan, Poland, South Africa, Croatia, Algeria, Australia, Bosnia and Herzegovina, ... and more
-
Novo Nordisk A/SCompletedEpidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries (HAEMOcare)Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia BIndia, Morocco, South Africa, Oman
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia BSpain
-
Novo Nordisk A/SWithdrawnHealthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B | Relatives to/Carers of PatientsSpain, Canada, United Kingdom
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia BUnited States
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B | Relatives to/Carers of PatientsBrazil
-
American Thrombosis and Hemostasis NetworkTakeda; CSL Behring; OctapharmaCompletedHemophilia A | Hemophilia B | Hemophilia | Hemophilia A With Inhibitor | Haemophilia | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
Clinical Trials on Experimental group
-
Finis Terrae UniversityNot yet recruitingPostoperative Pain | Respiratory ComplicationChile
-
Virginia Commonwealth UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedChronic Low Back Pain | Fear of Pain | Fear of InjuryUnited States
-
Riphah International UniversityCompletedSports Physical TherapyPakistan
-
Ataturk UniversityArtvin Coruh UniversityCompleted
-
Istanbul University - Cerrahpasa (IUC)Completed
-
Riphah International UniversityRecruitingEffects of Strength Training on Freestyle Swimming Performance and Core Muscles Strength in SwimmersSports Physical TherapyPakistan
-
Cristian AlvarezUniversidad de La FronteraCompleted
-
RezoluteActive, not recruitingDiabetic Macular EdemaUnited States
-
Ataturk UniversityNot yet recruitingQuality of Life | Fatigue | Gestational Diabetes Mellitus in Pregnancy | Pregnancy in Diabetic
-
Riphah International UniversityRecruiting